Evidence map›Paper›PMID 35578067›Full record

ArticleMedical oncology (Northwood, London, England)2022

Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo.

Miguel Mendivil-Perez, Marlene Jimenez-Del-Rio, Carlos Velez-Pardo

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Miguel Mendivil-PerezNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), SIU, Calle 70 No. 52-21, and Calle 62 # 52-59, Building 1, Room 412, Medellín, Colombia.ORCID http://orcid.org/0000-0002-8824-379X
Marlene Jimenez-Del-RioNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), SIU, Calle 70 No. 52-21, and Calle 62 # 52-59, Building 1, Room 412, Medellín, Colombia. marlene.jimenez@udea.edu.co.ORCID http://orcid.org/0000-0003-3477-2386
Carlos Velez-PardoNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), SIU, Calle 70 No. 52-21, and Calle 62 # 52-59, Building 1, Room 412, Medellín, Colombia. calberto.velez@udea.edu.co.ORCID http://orcid.org/0000-0002-0557-0411
Universidad de Antioquia · CO

Funding

Fundacion Alfonso Moreno Jaramillo 2020-31631
6 · The paper itself

Abstract

TPEN and TPGS have recently shown selective cytotoxic effects in vitro and ex vivo leukemia cells. In this study, we aimed to test the synergistic effect of combined TPEN and TPGS agents (thereafter, T2 combo) on Jurkat (clone-E61), K562, Ba/F3, and non-leukemia peripheral blood lymphocytes (PBL). The ED50 doses (i.e., TPEN ED50: 3.2 μM and TPGS ED50: 34 μM, potency ratio R = 10.62 = TPGS (ED50)/TPEN (ED50)) were identified as dose-effect curve (%DNA fragmentation (sub-G

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteApoptosisChildEthylenediaminesHumansJurkat CellsSignal TransductionVitamin EEthylenediaminesN,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediaminetocophersolanVitamin EAcute leukemiaCaspase-3Chronic leukemiaDJ-1LymphoblasticMyeloidSignalingTPENTPGS

Identifiers

PMID35578067
OpenAlexW4280559178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.